Sign in

You're signed outSign in or to get full access.

Todd Arden

Director at eHealtheHealth
Board

About Todd Arden

Todd Arden has served as an independent director of eHealth, Inc. (EHTH) since September 17, 2025, appointed as H.I.G.’s board designee; he currently sits on the Compensation, Nominating & Corporate Governance, and Government & Regulatory Affairs Committees . He is a credit and special situations investor and former Senior Managing Director and Co‑Chief Credit Officer at Black Diamond Capital Management (2016–2020), with prior roles at CCMP Capital (Chief Investment Officer – Octagon Credit Opportunities) and Angelo, Gordon & Co.; he holds a BA in Economics from Northwestern, an MBA from Columbia, and is a CFA charterholder . His tenure on EHTH’s board began in September 2025; age not disclosed in company materials .

Past Roles

OrganizationRoleTenureCommittees/Impact
Black Diamond Capital ManagementSenior Managing Director & Co‑Chief Credit OfficerJan 2016 – Mar 2020Led underwriting and credit exposures for alternative asset manager
CCMP Capital Advisors (Octagon Credit Opportunities)Chief Investment OfficerOct 2012 – Nov 2014Built credit opportunities strategy within a PE platform
Angelo, Gordon & Co.Managing Director, Distressed SecuritiesMar 2000 – Jun 2012Led investments in restructurings; served on multiple post‑reorg boards
AIG Global Investment CorpSenior Research/Portfolio roles (High Yield)Prior to 2000 (dates not specified)High yield credit research/PM
Troubh Partners LPSenior Equity AnalystPrior to 2000 (dates not specified)Equity analysis in distressed contexts
Arthur Andersen & Co. (NY)Manager, Financial Consulting ServicesPrior to 2000 (dates not specified)Distressed/litigation support

External Roles

OrganizationRoleTenureNotes
Quantum CorporationDirectorAppointed Jun 10, 2024Appointed by Quantum; public company directorship
Global Clean Energy HoldingsDirector (prior)Not disclosedDisclosed by EHTH; dates not provided
Private company boardsDirectorCurrentServes on several private boards (names not disclosed)

Board Governance

  • Committee assignments: Compensation Committee (member), Nominating & Corporate Governance Committee (member), Government & Regulatory Affairs Committee (member) .
  • Designation: Appointed as H.I.G.’s board designee following Aaron Tolson’s resignation; H.I.G. retains nomination rights under the Investment Agreement .
  • Independence considerations: Company risk factors caution that interests of an H.I.G.-designated director may differ from other security holders .
  • Attendance baseline: Board met nine times in 2024; all directors met ≥75% attendance except one Compensation Committee instance, but Arden joined in Sept 2025 (no 2024 attendance data for him) .

Fixed Compensation

ComponentStructureAmount/Terms
Company cash retainer – BoardAnnual retainer (pro rata for 2025 start)$100,000 cash annual retainer for non‑employee directors (effective mid‑2024 program)
Company cash retainers – CommitteesAnnual retainers (pro rata)Compensation Committee member $7,500; Nominating & Corporate Governance member $5,000; Government & Regulatory Affairs member $5,000
Company equity – Initial grantTime‑based RSUsGrant‑date value $150,000 of RSUs at appointment; vest in three equal annual installments over three years, subject to continued service
Travel expense reimbursementPolicyReasonable, customary, documented travel reimbursed by Company
Annual director equity cadence (program)Time‑based RSUsStandard annual RSUs valued at $175,000 with quarterly vesting cadence until next AGM; initial grants $175,000 vest annually over three years (program baseline)
H.I.G. third‑party compensationCash from H.I.G. (while serving as director)H.I.G. agreed to pay $35,000 per month less the company cash paid for that month, plus a $5,000 per diem under specified circumstances

Note: EHTH’s director program was amended in June 2024 to increase cash retainers and reduce annual equity grant size by $25,000; the table reflects current program levels .

Performance Compensation

ElementMetricsTerms
Director equity performance conditionsNone disclosed for non‑employee directorsDirector grants are time‑based RSUs; accelerated vesting upon change in control; no PSU/option performance metrics applied to director awards

Other Directorships & Interlocks

CompanyRelationship to EHTHRole/Committees
H.I.G. Capital (Echelon Health SPV, LP)Significant preferred equity investor with nomination rights; designated Arden to EHTH boardNot a board seat; investor designation; H.I.G. has additional rights due to covenant non‑compliance (see Risk Indicators)
Quantum CorporationUnrelated to EHTH operationsPublic company director (committees not disclosed)
Global Clean Energy HoldingsUnrelated to EHTH operationsPrior public company director

Expertise & Qualifications

  • Credit/distressed investing and capital markets: senior leadership at Black Diamond (Co‑Chief Credit Officer) and Angelo, Gordon; CIO role for Octagon Credit Opportunities at CCMP .
  • Board experience: service on multiple public and private boards, including Quantum Corporation and prior service at Global Clean Energy Holdings .
  • Education/credentials: BA (Northwestern), MBA (Columbia), CFA charterholder .

Equity Ownership

ItemDetail
Initial beneficial ownership (Form 3)Reported no securities beneficially owned as of Sept 17, 2025 event date
New‑director RSU grant$150,000 grant‑date value of time‑based RSUs; vesting annually over three years
Stock ownership guidelinesNon‑employee directors expected to hold a value equal to 5x annual board retainer (currently $375,000); achieve by June 30 following 4th anniversary; retention of 75% net shares until compliant
Hedging/pledgingInsider Trading Policy prohibits pledging, hedging, short sales and derivatives on Company stock

Insider Filings

FormFiling/Effective DateKey Facts
Form 3Filed Sept 19, 2025 (event 09/17/2025)Initial statement as Director; Table I shows “No securities beneficially owned”

Governance Assessment

  • Positives

    • Deep credit, restructuring, and capital allocation expertise; relevant to oversight of capital structure, financing, and risk management .
    • Broad committee engagement (Compensation, Nominating & Corporate Governance, Government & Regulatory Affairs), suggesting active role in key oversight areas .
    • Formal director ownership guidelines and anti‑hedging/pledging policy support alignment with long‑term shareholders .
    • No Company‑related related‑party transactions requiring Item 404(a) disclosure were reported upon his appointment .
  • Risk indicators and RED FLAGS

    • H.I.G. Influence and third‑party compensation: Arden was appointed as H.I.G.’s designee and receives monthly/ per‑diem compensation directly from H.I.G., in addition to Company retainers; Company risk factors warn an H.I.G.-designated director’s interests may diverge from common shareholders, and H.I.G. holds significant voting and preferential rights through Series A Preferred Stock (including redemption and consent rights) .
    • Covenant non‑compliance enhanced H.I.G. rights: EHTH’s prior failures to maintain the Minimum Asset Coverage Ratio (as of 9/30/2023) and Minimum Liquidity (as of 11/30/2024) entitle H.I.G. to additional rights (e.g., additional director nomination, approval rights over budget, key hires, and indebtedness) while it owns ≥30% of original preferred—implications for board autonomy and potential conflicts .
    • Capital structure overhang: Series A Preferred votes on an as‑converted basis and is convertible; potential dilution and governance influence risk .

Director Compensation Context (Program Benchmarks)

Element2024 Program Level
Non‑employee Board retainer (cash)$75,000 (raised by $25,000 in June 2024)
Board Chair additional retainer$50,000
Committee Chair retainersAudit $25,000; Compensation $15,000; Nominating & Corporate Governance $10,000; Government & Regulatory Affairs $10,000
Committee member retainersAudit $10,000; Compensation $7,500; Nominating & Corporate Governance $5,000; Government & Regulatory Affairs $5,000
Annual equity (directors)RSUs $175,000 grant-date value; time‑based vesting; accelerated vesting on change in control
Annual compensation cap$750,000 per director ($1,000,000 in initial year)

Say‑on‑Pay & Shareholder Feedback (Context)

  • 2024 say‑on‑pay approval received approximately 82.5% of votes cast (up from ~76.4% in 2023), reflecting improved support for compensation governance .

Board Governance Details (Company Reference)

  • Board met nine times in 2024; independent directors meet in regular executive sessions .
  • Committee charters and oversight scope: Audit (financial/cyber/ERM), Compensation (exec/director pay, clawback), Nominating & Corporate Governance (board composition/ESG/conflicts), Government & Regulatory Affairs (regulatory/public policy) .

Notes on Independence, Attendance, and Engagement

  • Independence status is not specifically stated for Arden; however, risk factors note that interests of an H.I.G.-designated director may differ from other shareholders, and he receives third‑party compensation from H.I.G. alongside Company director pay .
  • Attendance: No Arden‑specific attendance disclosure yet; he joined September 2025; 2024 attendance baselines provided above .